SecBot SecBot

EWTX drug pipeline

$45.93
+0.2% 1-day · Nov 13
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
4
1 mixed · 3 neutral
Phase 3 trials
0
0 with results posted

Upcoming catalysts

1 dated
  1. Jan 2027
    Sevasemten Dose 1
    Phase 2 primary completion

Drugs

soonest catalyst first
● neutral
Impact
PhasePhase 1
Time to marketUnlikely before 2029-2030 at earliest — Phase 1 data pending, Phase 2 not yet initiated, and HFpEF Phase 3 trials typically take years

EDG-15400 Updated Jul 13

What to watch

EDG-15400 is too early-stage to drive meaningful share price moves in the near term. Watch for the Phase 2 HFpEF trial initiation (expected H2 2026) and eventual Phase 2 data (H1 2027). For EWTX, the more impactful near-term catalyst is the EDG-7500 Phase 3 trial initiation in HCM (Q4 2026). EDG-15400 is a pipeline extension story for now.

Bull case
  • Novel mechanism targeting diastolic dysfunction directly, if successful, EDG-15400 would be first-in-class as a cardiac sarcomere modulator for HFpEF, a condition with no disease-modifying therapy that specifically targets the underlying mechanical dysfunction
  • HFpEF is a massive and growing market (~50% of all heart failure cases, $7.9B heart failure drug market in 2025 projected to reach $21.5B by 2036), and approved therapies like Entresto and SGLT2 inhibitors address it only indirectly
  • Edgewise is extremely well-capitalized after the $1.55B upfront from Servier (closed July 2026), eliminating financing risk for EDG-15400's development through Phase 2
Bear case
  • Phase 1 top-line data is still unreported as of mid-2026 (target was H1 2026), which raises questions about whether the data was clean, if safety/tolerability issues emerge, the program could be delayed or terminated
  • EDG-15400 is a secondary pipeline asset for Edgewise behind EDG-7500 (HCM), meaning its development timeline and resource allocation may deprioritize it if EDG-7500 requires more resources
  • HFpEF is a notoriously difficult indication for drug development, multiple high-profile programs have failed (including Novartis' Entresto struggling in some HFpEF studies), and the condition's heterogeneous patient population makes trial design challenging
◆ mixed
Impact
PhasePhase 2
Time to market4-6 years (Phase 2 completed; Phase 3 starting Q4 2026; if successful, NDA filing likely 2029-2030 at earliest)

EDG-7500 Updated Jul 13

What to watch

Edgewise is now a cardiovascular-focused single-product company after selling its muscular dystrophy business to Servier for $1.55B upfront. EDG-7500's Phase 2 safety data (no LVEF drops below 50% across all patients) is a genuine differentiator, but efficacy against BMS's approved Camzyos and Cytokinetics' pending aficamten remains unproven. Watch for Phase 3 start in Q4 2026 and any partnership/BD rumors for the program.

Bull case
  • No patient across Phase 1 and all Phase 2 cohorts experienced LVEF drop below 50%, a clean safety profile that could allow fixed dosing without the echo-guided dose titration required by Camzyos and aficamten, a significant commercial advantage.
  • The $1.55B upfront from Servier fully funds EDG-7500 development through potential approval with zero near-term dilution risk.
  • EDG-7500 showed efficacy in both obstructive AND nonobstructive HCM, there is no approved therapy for nonobstructive HCM, representing a large unmet-need market opportunity.
Bear case
  • Phase 2 12-week efficacy data disappointed relative to expectations, the stock fell ~10% on June 16, 2026 as investors compared results unfavorably to BMS's Camzyos (mavacamten, already approved with ~$1B annual sales) and Cytokinetics' aficamten (Phase 3 complete, awaiting regulatory decisions).
  • EDG-7500 is still in Phase 2, even with Phase 3 starting in Q4 2026, commercialization is likely 4-6 years away, and Phase 3 failure is a material risk despite promising Phase 2 safety.
  • Edgewise is now a single-product cardiovascular company after selling its muscular dystrophy franchise, any setback with EDG-7500 has no pipeline buffer.
● neutral
Impact
PhasePhase 2/3 (pivotal) for Becker muscular dystrophy; Phase 2 for Duchenne muscular dystrophy
Time to marketPotential FDA approval target end-2027 for Becker muscular dystrophy (if GRAND CANYON positive, NDA submission H1 2027). Duchenne program is earlier-stage (Phase 2).

sevasemten Updated Jul 13

What to watch

Sevasemten is no longer Edgewise's asset, it was sold to Servier. For EWTX holders, watch the GRAND CANYON readout (Q4 2026) which triggers up to $1.1B in milestone payments, but the stock's primary thesis now rests on the cardiovascular pipeline (EDG-7500). For non-EWTX investors, sevasemten's fate is in Servier's hands; there's no pure-play public stock directly tied to this drug.

Bull case
  • First and only approved therapy specifically for Becker muscular dystrophy if successful (no approved treatments currently exist), CureDuchenne.
  • Deal with Servier values the program at up to $2.65B, with $1.55B upfront cash already collected by Edgewise, strongly validates the science and derisks financing.
  • Phase 2 CANYON data showed 28% reduction in TNNI2 muscle damage biomarker and functional stabilization over 1 year, meeting its primary endpoint.
Bear case
  • The FDA previously declined accelerated approval for sevasemten in Becker, finding the Phase 2 data 'insufficient', meaning the bar for the GRAND CANYON data is high.
  • Edgewise has sold the drug, for EWTX holders, sevasemten is no longer the company's core asset. The $1.55B upfront is banked, but the stock's future thesis now rests on the early-stage cardiovascular pipeline (EDG-7500), not sevasemten.
  • Only $1.1B of the $2.65B deal value is contingent on regulatory and commercial milestones, if GRAND CANYON misses, those milestones vanish.
● neutral
Impact
PhasePreclinical / Discovery
Time to marketUnknown — preclinical discovery stage; likely 5+ years from any potential commercialization, if it advances at all.

EDG-003 Updated Jul 13

What to watch

EDG-003 is too early-stage to move the stock on its own in the next year. Investors should focus on EWTX's real catalysts: the Phase 3 initiation of EDG-7500 in HCM expected Q4 2026 and any milestone payments from the Servier sevasemten sale. EDG-003 is a pipeline filler at the discovery stage, no trading thesis can be built around it.

Bull case
  • Edgewise just completed a $1.55B upfront cash deal with Servier, giving it a strong balance sheet to fund early discovery work like EDG-003 through potential approval of its lead assets.
  • The EDG-003 discovery program already produced one winner, EDG-7500, now in Phase 2/3 for HCM, suggesting the platform can identify viable drug candidates.
  • Cardiometabolic disease is a massive market, and if EDG-003 yields a novel therapy, it could open a significant commercial opportunity.
Bear case
  • EDG-003 is at the preclinical discovery stage, no IND filed, no clinical trials, no public data. It's impossible to assess whether any candidate will be viable.
  • The target indication is undisclosed, meaning investors cannot evaluate the competitive landscape or addressable market for this specific program.
  • Edgewise's stock is driven almost entirely by EDG-7500 (HCM) catalysts. EDG-003 is immaterial to near-term valuation and won't move the stock.

Clinical trials

3 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
Sevasemten Dose 1A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)Phase 2Active not recruiting76Jan 2027
sevasemtenPhase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)Phase 2Completed244Sep 7, 2026
EDG-7500A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)Phase 2Active not recruiting100Jun 2026